-
公开(公告)号：US20230060003A1
公开(公告)日：2023-02-23
申请号：US17772646
申请日：2020-10-28
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Lei Zhang , Zhili Xin , Jeffrey Vessels , Ryan Gianatassio
IPC: C07D491/107 , C07D491/20 , C07D417/06
Abstract: Described herein are compounds represented by formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R2, R3, R4, R5, R6, Y1, Y2, D, E, G1, G2, n and p are as defined herein.
-
公开(公告)号：US20220259197A1
公开(公告)日：2022-08-18
申请号：US17435125
申请日：2020-03-06
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , C07D495/04
Abstract: Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical comositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, and Z are as defined herein.
-
公开(公告)号：US20210040080A1
公开(公告)日：2021-02-11
申请号：US16978550
申请日：2019-03-13
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , C07D471/04 , C07D417/06
Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
-
公开(公告)号：US20190209592A1
公开(公告)日：2019-07-11
申请号：US16182845
申请日：2018-11-07
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras
IPC: A61K31/695 , A61K31/11 , C07F7/08 , A61K31/165 , A61K31/137 , A61K31/235 , A61K31/223 , C07D401/06 , C07D277/64 , C07D239/74 , C07D217/04 , C07D215/227 , C07C255/54 , C07C47/575 , C07C43/247 , A61K45/06 , A61K31/683 , A61K31/662 , A61K31/517 , A61K31/472 , A61K31/4709 , A61K31/47 , A61K31/445 , A61K31/428 , A61K31/41 , A61K31/404 , A61K31/40 , A61K31/397 , A61K31/337 , A61K31/277 , A61K31/216 , A61K31/197 , A61K31/18 , C07F9/38 , A61K31/085 , C07F9/40 , C07D417/06 , C07D403/06 , C07D305/08 , C07D257/04 , C07D217/24 , C07D215/20 , C07D211/62 , C07D211/60 , C07D209/08 , C07D207/16 , C07D205/04 , C07C311/51 , C07C309/14 , C07C237/52 , C07C237/08 , C07C229/48 , C07C229/46 , C07C229/22 , C07C229/14 , A61K31/401 , A61K31/185 , A61K31/198 , A61K31/222
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
-
公开(公告)号：US10017506B2
公开(公告)日：2018-07-10
申请号：US15296601
申请日：2016-10-18
Applicant: BIOGEN MA INC.
Inventor： Kevin M. Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur G. Taveras , Deping Wang , Zhili Xin , Lei Zhang
IPC: A61K31/015 , A61K31/4375 , A61K31/44 , C07D451/02 , C07D217/22 , A61K31/472 , A61K45/06 , A61K31/4725 , C07D401/06
CPC classification number: C07D451/02 , A61K31/136 , A61K31/196 , A61K31/439 , A61K31/445 , A61K31/46 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C217/22 , C07C229/46 , C07C229/48 , C07C255/59 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/52 , C07D211/34 , C07D211/62 , C07D217/22 , C07D221/22 , C07D223/06 , C07D295/096 , C07D401/06 , C07D471/08 , Y02A50/401
Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
-
Patent Agency Ranking
公开(公告)号：US20180133233A1
公开(公告)日：2018-05-17
申请号：US15783809
申请日：2017-10-13
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras
IPC: A61K31/695 , A61K31/11 , C07F7/08 , C07D401/06 , C07D277/64 , C07D239/74 , C07D217/04 , C07D215/227 , C07C255/54 , C07C47/575 , C07C43/247 , A61K45/06 , A61K31/683 , A61K31/662 , A61K31/517 , A61K31/472 , A61K31/4709 , A61K31/47 , A61K31/445 , A61K31/428 , A61K31/41 , A61K31/404 , A61K31/40 , A61K31/397 , A61K31/337 , A61K31/277 , A61K31/216 , A61K31/197 , A61K31/18 , C07F9/38 , A61K31/085 , C07F9/40 , C07D417/06 , C07D403/06 , C07D305/08 , C07D257/04 , C07D217/24 , C07D215/20 , C07D211/62 , C07D211/60 , C07D209/08 , C07D207/16 , C07D205/04 , C07C311/51 , C07C309/14 , C07C237/52 , C07C237/08 , C07C229/48 , C07C229/46 , C07C229/22 , C07C229/14 , A61K31/401 , A61K31/185 , A61K31/198 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/137 , A61K31/165
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
-
公开(公告)号：US20240308995A1
公开(公告)日：2024-09-19
申请号：US18673619
申请日：2024-05-24
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , A61P25/28 , C07D417/06
CPC classification number: C07D417/14 , A61P25/28 , C07D417/06
Abstract: Described herein are compounds represented by formulas (IA) or (IB)
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.-
公开(公告)号：US11427561B2
公开(公告)日：2022-08-30
申请号：US16071200
申请日：2017-01-18
Applicant: BIOGEN MA INC.
Inventor： Timothy Chan , Kevin M. Guckian , Tracy Jenkins , Jermaine Thomas , Jeffrey Vessels , Gnanasambandam Kumaravel , Robert Meissner , Joseph P. Lyssikatos , Brian Lucas , Irina Leaf , Jeremy Duffield , Nathan Genung
IPC: C07D401/14 , A61K45/06
Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.
-
公开(公告)号：US10406144B2
公开(公告)日：2019-09-10
申请号：US16020696
申请日：2018-06-27
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Sha Mi , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel
IPC: A61K31/445 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K39/395 , A61K38/21 , C07D211/34 , C07D211/60 , C07D211/62 , C07D401/06 , C07D405/12 , C07D215/20 , C07K16/28
Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
-
公开(公告)号：US20180369215A1
公开(公告)日：2018-12-27
申请号：US16020696
申请日：2018-06-27
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Sha Mi , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel
IPC: A61K31/445 , A61K31/517 , C07D211/34 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/55 , A61K31/225 , A61K31/695 , C07K16/28 , A61K38/21 , A61K39/395 , C07D215/20 , C07D405/12 , C07D401/06 , C07D211/62 , C07D211/60
CPC classification number: A61K31/445 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/3955 , C07D211/34 , C07D211/60 , C07D211/62 , C07D215/20 , C07D401/06 , C07D405/12 , C07K16/2842
Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.029 seconds)
